Cargando…
F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review
PURPOSE: The aim of this systematic review was to systematically assess the potential patient-relevant benefit (primary aim) and diagnostic and prognostic accuracy (secondary aim) of positron emission tomography (PET) and PET/computed tomography (CT) in primary staging of malignant melanoma. This sy...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536719/ https://www.ncbi.nlm.nih.gov/pubmed/23237499 http://dx.doi.org/10.1186/2046-4053-1-62 |
_version_ | 1782254796861865984 |
---|---|
author | Schröer-Günther, Milly A Wolff, Robert F Westwood, Marie E Scheibler, Fülöp J Schürmann, Christoph Baumert, Brigitta G Sauerland, Stefan Kleijnen, Jos |
author_facet | Schröer-Günther, Milly A Wolff, Robert F Westwood, Marie E Scheibler, Fülöp J Schürmann, Christoph Baumert, Brigitta G Sauerland, Stefan Kleijnen, Jos |
author_sort | Schröer-Günther, Milly A |
collection | PubMed |
description | PURPOSE: The aim of this systematic review was to systematically assess the potential patient-relevant benefit (primary aim) and diagnostic and prognostic accuracy (secondary aim) of positron emission tomography (PET) and PET/computed tomography (CT) in primary staging of malignant melanoma. This systematic review updates the previous evidence for PET(/CT) in malignant melanoma. MATERIALS AND METHODS: For the first aim, randomized controlled trials (RCTs) investigating patient-relevant outcomes and comparing PET and PET(/CT) with each other or with conventional imaging were considered. For the secondary aim, a review of reviews was conducted, which was amended by an update search for primary studies. MEDLINE, EMBASE and four databases of the Cochrane Library were searched. The risk of bias was assessed using a modified QUADAS tool. RESULTS: No RCTs investigating the patient-relevant benefit of PET(/CT) and no prognostic accuracy studies were found. Seventeen diagnostic accuracy studies of varying quality were identified. For patients with American Joint Committee on Cancer (AJCC) stages I and II, sensitivity mostly ranged from 0 to 67%. Specificity ranged from 77 to 100%. For AJCC stages III and IV, sensitivity ranged from 68 to 87% and specificity from 92 to 98%. CONCLUSION: There is currently no evidence of a patient-relevant benefit of PET(/CT) in the primary staging of malignant melanoma. RCTs investigating patient-relevant outcomes are therefore required. The diagnostic accuracy of PET(/CT) appears to increase with higher AJCC stages. |
format | Online Article Text |
id | pubmed-3536719 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-35367192013-01-08 F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review Schröer-Günther, Milly A Wolff, Robert F Westwood, Marie E Scheibler, Fülöp J Schürmann, Christoph Baumert, Brigitta G Sauerland, Stefan Kleijnen, Jos Syst Rev Systematic Review Update PURPOSE: The aim of this systematic review was to systematically assess the potential patient-relevant benefit (primary aim) and diagnostic and prognostic accuracy (secondary aim) of positron emission tomography (PET) and PET/computed tomography (CT) in primary staging of malignant melanoma. This systematic review updates the previous evidence for PET(/CT) in malignant melanoma. MATERIALS AND METHODS: For the first aim, randomized controlled trials (RCTs) investigating patient-relevant outcomes and comparing PET and PET(/CT) with each other or with conventional imaging were considered. For the secondary aim, a review of reviews was conducted, which was amended by an update search for primary studies. MEDLINE, EMBASE and four databases of the Cochrane Library were searched. The risk of bias was assessed using a modified QUADAS tool. RESULTS: No RCTs investigating the patient-relevant benefit of PET(/CT) and no prognostic accuracy studies were found. Seventeen diagnostic accuracy studies of varying quality were identified. For patients with American Joint Committee on Cancer (AJCC) stages I and II, sensitivity mostly ranged from 0 to 67%. Specificity ranged from 77 to 100%. For AJCC stages III and IV, sensitivity ranged from 68 to 87% and specificity from 92 to 98%. CONCLUSION: There is currently no evidence of a patient-relevant benefit of PET(/CT) in the primary staging of malignant melanoma. RCTs investigating patient-relevant outcomes are therefore required. The diagnostic accuracy of PET(/CT) appears to increase with higher AJCC stages. BioMed Central 2012-12-13 /pmc/articles/PMC3536719/ /pubmed/23237499 http://dx.doi.org/10.1186/2046-4053-1-62 Text en Copyright ©2012 Schröer-Günther et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Systematic Review Update Schröer-Günther, Milly A Wolff, Robert F Westwood, Marie E Scheibler, Fülöp J Schürmann, Christoph Baumert, Brigitta G Sauerland, Stefan Kleijnen, Jos F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review |
title | F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review |
title_full | F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review |
title_fullStr | F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review |
title_full_unstemmed | F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review |
title_short | F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review |
title_sort | f-18-fluoro-2-deoxyglucose positron emission tomography (pet) and pet/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review |
topic | Systematic Review Update |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536719/ https://www.ncbi.nlm.nih.gov/pubmed/23237499 http://dx.doi.org/10.1186/2046-4053-1-62 |
work_keys_str_mv | AT schroergunthermillya f18fluoro2deoxyglucosepositronemissiontomographypetandpetcomputedtomographyimaginginprimarystagingofpatientswithmalignantmelanomaasystematicreview AT wolffrobertf f18fluoro2deoxyglucosepositronemissiontomographypetandpetcomputedtomographyimaginginprimarystagingofpatientswithmalignantmelanomaasystematicreview AT westwoodmariee f18fluoro2deoxyglucosepositronemissiontomographypetandpetcomputedtomographyimaginginprimarystagingofpatientswithmalignantmelanomaasystematicreview AT scheiblerfulopj f18fluoro2deoxyglucosepositronemissiontomographypetandpetcomputedtomographyimaginginprimarystagingofpatientswithmalignantmelanomaasystematicreview AT schurmannchristoph f18fluoro2deoxyglucosepositronemissiontomographypetandpetcomputedtomographyimaginginprimarystagingofpatientswithmalignantmelanomaasystematicreview AT baumertbrigittag f18fluoro2deoxyglucosepositronemissiontomographypetandpetcomputedtomographyimaginginprimarystagingofpatientswithmalignantmelanomaasystematicreview AT sauerlandstefan f18fluoro2deoxyglucosepositronemissiontomographypetandpetcomputedtomographyimaginginprimarystagingofpatientswithmalignantmelanomaasystematicreview AT kleijnenjos f18fluoro2deoxyglucosepositronemissiontomographypetandpetcomputedtomographyimaginginprimarystagingofpatientswithmalignantmelanomaasystematicreview |